Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto

Drug Profile

Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto

Latest Information Update: 10 Dec 2016

Price : $50

At a glance

  • Originator Advanced Proteome Therapeutics
  • Developer Advanced Proteome Therapeutics; Toronto Recombinant Antibody Centre
  • Class Antibodies; Antineoplastics; Drug conjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Oct 2016 Preclinical trials in Cancer in USA (Parenteral)
  • 19 Oct 2016 Advanced Proteome Therapeutics enter into an option agreement with the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto (UT) to license validated antibody candidates suited for development of antibody-drug conjugates for treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top